HLA-DMB and colitis: DMB‐driven GSDMD activation and GSDMD overexpression with plasmids substantially attenuated miR‐5119′s inhibitory effects on NET formation (Figure 10b–e), and compromised its therapeutic efficacy in alleviating colitis (Figure 10f–n).